Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.
Bitcoin’s mining power surged to record levels, but with fewer transactions filling blocks and the cryptocurrency’s price weakness, the rising hashrate may not translate to sustained profitability for miners.
The GBP/USD pair climbed to 1.3064 on Thursday, marking a 2.46% gain over the past four weeks and a 2.87% increase against the US dollar over the last 12 months.
The seat belt pretensioner in the vehicles may inadvertently lock the belt, not allowing it to retract or extend, and increasing the risk of injury in case of crash.
Founder & CEO of Professional Capital Management, Anthony Pompliano has praised the new tariffs introduced by President Donald Trump on Wednesday, arguing that they highlight the inefficiencies of traditio
(BPT) - Great businesses thrive in great communities. But how can a fashion retailer make a difference? Ross Dress for Less® and the Ross Stores Foundation found the answer by focusing on the future.
A new study from Aimed Alliance and HR.com’s HR Research Institute highlights the career impact of menopause and the need for supportive workplace policies
While the gold price is breaking records and has just passed the symbolic threshold of $3,000 an ounce, Bitcoin is struggling and looking for its second wind.
Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether ALPHABET INC-CL C (NASDAQ:GOOG) fits his legendary investment approach.
Packaged foods company Conagra Brands (NYSE:CAG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 6.3% year on year to $2.84 billion. Its non-GAAP profit of $0.51 per share was 3.3% below analysts’ consensus estimates.
The brokerage highlighted that since its public listing in April 2024, the company has mostly exceeded consensus expectations and continued executing its organic and inorganic growth strategy.
Peter Lynch favored companies with strong earnings growth, reasonable valuations, and solid financials. In this analysis, we’ll determine if INTERPARFUMS INC (NASDAQ:IPAR) qualifies as a true Lynch-style investment.
